Molecular profiling company Caris Life Sciences has secured a USD 400 million term loan from its existing investor OrbiMed and Braidwell. This brings the total funds raised by the company to USD 1.7 billion. OrbiMed also took part in Caris' USD 830 million equity financing round in 2021, as well as its USD 310 million growth capital financing round in 2020.
The new funds will be used towards settling its outstanding debt, advancing its technological platform, and for corporate expenses.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.